A new study published in the Journal of Medical Internet Research has found that regular participation in dance classes can ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Parkinson’s disease is the second most common neurodegenerative brain ... Furthermore, sleep disturbances were found to worsen the severity of “OFF periods,” the times when the effects of Parkinson’s ...

Aug. 5, 2024 — A research team examined the effect of Ecklonia cava polyphenols on the prevention of Parkinson's disease. It was found that the oral intake of the seaweed antioxidants restores ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...